ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2015 Results and Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. MRNA
9. LVS
10. MRK

Go back to ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2015 Results and Highlights

Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy

November 4, 2015 8:13 AM EST

Roth Capital maintained a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and cut the price target to $56.00 (from $60.00), following the company's 3Q15 earnings report. ANIP reported 3Q15 revenues of $20 million, which trailed consensus of $21.4M. The downside appeared to come from non-core branded revenues. Management... More

ANI Pharma (ANIP) Tops Q3 EPS by 17c

November 3, 2015 9:14 AM EST

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.80, $0.17 better than the analyst estimate of $0.63. Revenue for the quarter came in at $20 million versus the consensus estimate of $21.37 million.

ANI Pharma sees Q4 2015 EPS of $0.60-$0.76, versus the consensus of $0.70. ANI Pharma sees Q4 2015... More